Decreased β-Cell Function is Associated with Cardiovascular Autonomic Neuropathy in Chinese Patients Newly Diagnosed with Type 2 Diabetes

Xubin Yang1, Wen Xu1, Yanhua Zhu1, Hongrong Deng1, Ying Tan1, Longyi Zeng1, Jianping Weng1

Received: 19 April 2018 / Accepted: 8 September 2018 / Published online: 15 November 2018 © The Author(s) 2018

Abstract The influence of β-cell function on cardiovascular autonomic neuropathy (CAN), an important diabetes-related complication, is still unclear. In this study, we aimed to investigate the association between residual β-cell function and CAN in patients newly diagnosed with type 2 diabetes. We enrolled 90 newly-diagnosed type 2 diabetic patients and 37 participants with normal glucose tolerance as controls. The patients were divided into a CAN+ group (diabetic patients with CAN, n = 20) and a CAN− group (diabetic patients without CAN, n = 70) according to the standard Ewing battery of tests. Fasting and postprandial plasma glucose, insulin, and C-peptide were measured. Homeostasis model assessment-beta cells (HOMA-B) and HOMA-insulin resistance (IR) were calculated. The prevalence of CAN in this population was 22.2%. Compared with the CAN− group, the CAN+ group had significantly lower fasting plasma insulin (6.60 ± 4.39 vs 10.45 ± 7.82 μL, P = 0.029), fasting C-peptide (0.51 ± 0.20 vs 0.82 ± 0.51 nmol/L, P = 0.004), and HOMA-B (21.44 ± 17.06 vs 44.17 ± 38.49, P = 0.002). Fasting C-peptide was correlated with the Valsalva ratio (r = 0.24, P = 0.043) and the 30:15 test (r = 0.26, P = 0.023). Further analysis showed that fasting C-peptide (OR: 0.041, 95% CI 0.003–0.501, P = 0.012) and HOMA-B (OR: 0.965, 95% CI 0.934–0.996, P = 0.028) were independently associated with cardiovascular autonomic nerve function in this population. The patients with fasting C-peptide values < 0.67 nmol/L were more likely to have CAN than those with C-peptide levels ≥0.67 nmol/L (OR: 6.00, 95% CI 1.815–19.830, P = 0.003). A high prevalence of CAN was found in patients with newly-diagnosed type 2 diabetes. Decreased β-cell function was closely associated with CAN in this population.

Keywords Cardiovascular autonomic neuropathy · β-cell function · Type 2 diabetes mellitus

Introduction

Cardiovascular autonomic neuropathy (CAN), one of the most important diabetes-related complications, is closely associated with increased cardiovascular morbidity and mortality in patients with diabetes [1]. Prevention or delay of the development of CAN is clinically important [2]. However, the characteristics and risk factors of CAN are not completely clear in type 2 diabetes [1]. Although hyperglycemia is generally accepted to be the major cause of CAN [2], substantial numbers of patients with tight glycemic control still experience the progressive development of CAN, suggesting that other factors besides chronic sustained hyperglycemia play roles in the development of CAN [3]. Identification of the characteristics and the related risk factors of CAN is important to prevent or delay CAN in diabetic patients, especially at the early stage of the disease.

In recent years, both insulin and C-peptide (a peptide cleaved from proinsulin and eventually released into the bloodstream in amounts equimolar with those of insulin) have been shown to exert various influences on anti-apoptosis, metabolic diseases, and nervous system diseases.
The deterioration of β-cell function has been demonstrated to be associated with diabetic complications [8]. A previous study showed that C-peptide administration significantly improves autonomic nerve function in type 1 diabetes [9]. However, the pathophysiology of type 1 and type 2 diabetes is fundamentally different. Whether the same association of β-cell function with autonomic nerve function also occurs in patients with type 2 diabetes is poorly studied. Some studies found an association of better residual insulin secretion with decreased incidence of CAN in type 2 diabetic patients, while others did not [10–12]. Therefore, we conducted this post hoc analysis of our previously published multicenter, cross-sectional study to investigate the association between residual β-cell function and CAN in newly-diagnosed type 2 diabetic patients.

Materials and Methods

Participants

Details of the inclusion criteria and methods of this study have been published previously [13]. Briefly, the participants were enrolled from four university-affiliated hospitals in Guangdong Province, China. Ninety drug-naïve patients newly diagnosed with type 2 diabetes were enrolled as the diabetes group. Exclusion criteria included uncontrolled hypertension, congestive heart failure, cardiac arrhythmias, stroke, severe liver insufficiency or renal insufficiency, proliferative retinopathy, psychiatric disease, anemia, on β-blocker or digitalis treatment within a month, pregnancy, and addiction to alcohol, cigarettes, or coffee. Forty participants with normal glucose tolerance and normal blood pressure were selected as the control group. The protocol was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University. All participants provided written informed consent before screening.

Measurements

All the measurements were made after a 10-h overnight fast. Waist circumference, hip circumference, and blood pressure were measured while participants were barefoot and wearing light clothes after defecation. Blood samples were collected before and 2 h after a fixed breakfast (~300 kcal) for measurement of hemoglobin A1c (HbA1c), fasting lipid profile, fasting and 2-h postprandial plasma glucose (2hPPG), insulin, and C-peptide. Fasting and postprandial plasma glucose levels, lipid concentrations for total cholesterol, triglycerides, and HDL-cholesterol (HDL-c) were measured using an automated enzymatic method (7600-020 Chemical Analyzer, Hitachi, Japan). HbA1c levels were determined by high-performance liquid chromatography (D-10 analyzer, Bio-Rad, Hercules, CA). Fasting and 2-h postprandial plasma insulin and C-peptide were measured by radioimmunoassay (Centaur XP immunoassay system, Siemens Healthcare Diagnostics, New York, NY).

Homoeostasis model assessment (HOMA) was used to estimate basal β-cell function (HOMA-B) and insulin resistance (HOMA-IR). HOMA-B was calculated as [20× fasting insulin (FINS)] / [fasting plasma glucose (FPG)—3.5]. HOMA-IR was calculated as FPG × FINS / 22.5 [14].

Assessment of Cardiovascular Autonomic Neuropathy

Smoking and drinking coffee, wine, or tea were prohibited for at least 24 h before the tests. The tests were performed between 08:30 and 16:00 at least 2 h after breakfast in a quiet room with a temperature of 23–25°C. The standard Ewing battery of tests [15], including the Valsalva maneuver (Valsalva ratio), the deep breathing test of expiration-to-inspiration ratio (E/I test), and the lying-to-standing test (30:15 test) among the heart rate tests, and the orthostatic hypotension test, were conducted for every participant by well-trained investigators at each site who were blind to the individual’s laboratory results (details in Table 1). Sympathetic nerve dysfunction was identified by the orthostatic hypotension test, while parasympathetic nerve dysfunction was identified by the other three Ewing tests. When the autonomic nerve function was impaired, the indexes of the orthostatic hypotension test increased while the other three indexes decreased. The scores from Ewing tests were used to classify the severity of CAN (Table 2): each Ewing test was graded as normal (score = 0), borderline (score = 0.5), or abnormal (score = 1). The total score on each of the Ewing tests was calculated. The participants whose total score was ≥ 2 were considered to have CAN. Therefore, patients in the diabetes group were further divided into two sub-groups: those without CAN (CAN−) and those with CAN (CAN+). Participants with a total score ≥ 2 in the control group were excluded from further analysis to avoid any confounding impact.

Statistical Analysis

Continuous variables with a normal distribution are presented as mean ± SD. Differences between the diabetes and control groups were compared with unpaired t-tests. ANOVA tests with the LSD t-test were used to analyze differences among the CAN+, CAN−, and control groups. Pearson’s correlation coefficient was used to investigate the associations between the indexes of the Ewing tests and the indexes of residual β-cell function. The upper quartile
value for fasting plasma C-peptide in the CAN+ group was 0.67 nmol/L. Accordingly, patients were separated based on the two strata of fasting plasma C-peptide levels: patients with fasting C-peptide level ≥ 0.67 nmol/L and those with fasting C-peptide < 0.67 nmol/L. Multivariate analysis was performed by binary logistic regression with CAN as the dependent variable, fasting and 2-h postprandial plasma insulin and C-peptide levels, HOMA-B, HOMA-IR, and fasting plasma C-peptide strata as the independent variables to identify the factors for CAN, shown as odds ratios (OR) with 95% confidence intervals (CI). All statistical analyses were conducted with SPSS 21.0. Significance was defined as P < 0.05.

### Results

| Test                              | Normal     | Borderline | Abnormal |
|-----------------------------------|------------|------------|----------|
| Valsalva ratio                    | ≥ 1.21     | 1.11–1.20  | ≤ 1.10   |
| E/I                              | ≥ 15 beats/min | 11–14 beats/min | ≤ 10 beats/min |
| 30:15                            | ≥ 1.04     | 1.01–1.03  | ≤ 1.00   |
| Orthostatic hypotension test      | ≤ 10 mmHg  | 11–29 mmHg | ≥ 30 mmHg|

E/I, deep-breathing test (expiration-to-inspiration ratio); 30:15, lying-to-standing test.  

Prevalence and Characteristics of Cardiovascular Autonomic Neuropathy in Patients Newly Diagnosed with Type 2 Diabetes

The results of Ewing tests in different groups are shown in Table 3. Among the diabetic patients, 22.2% (20/90) were diagnosed with CAN. From the scores of different Ewing tests, we found that the proportion of type 2 diabetic patients with abnormal sympathetic nerve function was lower than that of patients with abnormal parasympathetic nerve function. Three out of 40 participants in the control group with a total score ≥ 2 were excluded as predefined. The index of orthostatic hypotension test in the diabetes group was significantly higher than that in the control group (P = 0.015). All the indexes of Ewing tests differed significantly between the CAN+ group and the control group. When comparing the CAN− and control groups, only the index of the orthostatic hypotension test was different.

### Anthropometric and Other Laboratory Characteristics of Participants

The anthropometric and other laboratory characteristics of participants are shown in Table 4. When compared with the control group, patients in the CAN+ group were older (P = 0.001), had higher waist circumference to hip circumference ratio (WHR) (P = 0.001), FPG (P < 0.001), 2hPPG (P < 0.001), HBA1c (P < 0.001), and heart rate (P = 0.012), while patients in the CAN− group had higher WHR (P = 0.006), heart rate (P = 0.013), systolic blood pressure (P = 0.003), diastolic blood pressure (P = 0.016), FPG (P < 0.001), 2hPPG (P < 0.001), and HBA1c (P < 0.001) but lower HDL-c (P = 0.010). In the diabetes group, patients in the CAN+ group were older (P < 0.001) than those in the CAN− group.

### Comparison of β-Cell Function and Insulin Resistance Among Groups

Compared with the control group, patients in the CAN+ group had lower HOMA-B (21.44 ± 17.06 VS 124.58 ± 55.04, P < 0.001) but higher HOMA-IR (3.14 ± 2.09 VS 1.80 ± 0.84, P = 0.030); and the CAN− group had lower HOMA-B (44.17 ± 38.49 VS 124.58 ± 55.04, P < 0.001) but higher fasting plasma C-peptide (0.82 ± 0.51 VS 0.42 ± 0.15 nmol/L, P < 0.001)
Table 3 Ewing test indexes in different groups.

| Ewing test indexes                          | Diabetes group (n = 90) | Abnormality proportion of each index n (%) | Control group (n = 37) | P value   |
|--------------------------------------------|-------------------------|------------------------------------------|------------------------|-----------|
|                                            | CAN+ (n = 20)           | CAN- (n = 70)                            | Whole group            |           |
| Valsalva ratio                             | 1.11 ± 0.15             | 1.32 ± 0.26                              | 1.27 ± 0.25            | 29 (32.2) |
|                                            |                         |                                           |                        | 1.41 ± 0.24 | 0.015     | <0.001   | 0.119    | 0.001    |
| E/I(beats/min)                             | 9.08 ± 5.76             | 14.47 ± 5.62                             | 13.07 ± 6.10           | 30 (33.3)  | 15.24 ± 7.89 | 0.160     | 0.002    | 0.613    | 0.001    |
| 30:15                                      | 1.04 ± 0.07             | 1.15 ± 0.19                              | 1.12 ± 0.18            | 9 (10)     | 1.19 ± 0.13  | 0.120     | 0.003    | 0.432    | 0.001    |
| Orthostatic hypotension test (mmHg)        | 8.90 ± 8.67             | 5.17 ± 5.73                              | 6.13 ± 6.75            | 1 (1.1)    | 2.19 ± 3.09  | 0.008     | <0.001   | 0.049    | 0.018    |

CAN+, type 2 diabetic patients with cardiovascular autonomic neuropathy; CAN−, type 2 diabetic patients without cardiovascular autonomic neuropathy; E/I, deep-breathing test (expiration-to-inspiration ratio); 30:15, lying-to-standing test.

Table 4 Anthropometric and laboratory characteristics of participants.

| Anthropometric and laboratory characteristics of participants. | Diabetes group (n = 90) | Control group (n = 37) | P value   |
|---------------------------------------------------------------|-------------------------|------------------------|-----------|
|                                                              | CAN+ (n = 20)           | CAN- (n = 70)          | Whole group |           |
|                                                              |                         |                        |            |           |
| BMI (kg/m²)                                                  | 25.01 ± 4.05            | 25.26 ± 3.48           | 26.20 ± 3.59 | 24.56 ± 2.83 | 0.338 | 0.636 | 0.320 | 0.812    |
| WHR                                                          | 0.97 ± 0.06             | 0.97 ± 0.06            | 0.97 ± 0.06 | 0.93 ± 0.08  | 0.003 | 0.015 | 0.006 | 0.651    |
| age (years)                                                  | 53.70 ± 8.40            | 44.75 ± 9.54           | 46.71 ± 9.98 | 44.65 ± 10.74 | 0.301 | 0.001 | 0.961 | <0.001   |
| Heart rate (beats/min)                                       | 79.90 ± 9.83            | 77.99 ± 10.12          | 78.42 ± 10.03 | 73.03 ± 8.73  | 0.005 | 0.012 | 0.013 | 0.439    |
| SBP (mmHg)                                                   | 129.40 ± 15.05          | 131.91 ± 16.65         | 131.35 ± 16.26 | 122.49 ± 11.89 | 0.003 | 0.103 | 0.003 | 0.516    |
| DBP (mmHg)                                                   | 78.65 ± 10.38           | 82.09 ± 11.69          | 81.31 ± 11.45 | 76.57 ± 10.13  | 0.030 | 0.499 | 0.016 | 0.224    |
| TG (mmol/L)                                                  | 2.27 ± 1.82             | 2.92 ± 2.91            | 2.77 ± 2.71 | 2.05 ± 1.37   | 0.141 | 0.741 | 0.080 | 0.294    |
| TC (mmol/L)                                                  | 5.40 ± 1.18             | 5.15 ± 0.85            | 5.21 ± 0.93 | 5.11 ± 0.89   | 0.571 | 0.254 | 0.802 | 0.296    |
| HDL-c (mmol/L)                                               | 1.24 ± 0.28             | 1.13 ± 0.29            | 1.15 ± 0.29 | 1.29 ± 0.31   | 0.021 | 0.500 | 0.010 | 0.173    |
| LDL-c (mmol/L)                                               | 3.07 ± 0.80             | 3.16 ± 0.77            | 3.20 ± 0.84 | 3.04 ± 0.81   | 0.323 | 0.222 | 0.461 | 0.457    |
| FPG (mmol/L)                                                 | 10.86 ± 2.92            | 9.78 ± 3.63            | 10.02 ± 3.49 | 4.86 ± 0.32   | <0.001 | <0.001 | <0.001 | 0.146    |
| 2hPPG (mmol/L)                                               | 17.73 ± 5.19            | 15.46 ± 5.14           | 15.91 ± 5.19 | 5.85 ± 1.05   | <0.001 | <0.001 | <0.001 | 0.077    |
| HBA1c (%)                                                    | 9.53 ± 2.14             | 9.21 ± 2.06            | 9.28 ± 2.07 | 5.38 ± 0.47   | <0.001 | <0.001 | <0.001 | 0.474    |

CAN+, type 2 diabetic patients with cardiovascular autonomic neuropathy; CAN−, type 2 diabetic patients without cardiovascular autonomic neuropathy; BMI, body mass index; WHR, waist-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; FBG, fasting blood glucose; 2hPPG, 2-h postprandial plasma glucose; HBA1c, hemoglobin A1c.

and HOMA-IR (4.36 ± 3.43 vs 1.80 ± 0.84, P < 0.001) (Fig. 1). In the diabetes group, FINS, fasting plasma C-peptide, and HOMA-B in the CAN+ group were significantly lower than those in the CAN− group (FINS: 6.60 ± 4.39 vs 10.45 ± 7.82 μmol/L, P = 0.029; fasting plasma C-peptide 0.51 ± 0.20 vs 0.82 ± 0.51 nmol/L, P = 0.004; and HOMA-B 21.44 ± 17.06 vs 44.17 ± 38.49, P = 0.002). There was no significant difference in HOMA-IR between the CAN+ and CAN− groups.

**Pearson’s Correlation Between Ewing Test Indexes and Residual β-Cell Function**

Pearson’s correlation between the Ewing test indexes and residual β-cell function indexes (Table 5) showed that

 Springer
fasting C-peptide was positively correlated with Valsalva ratio in the CAN+ group ($r = 0.48$, $P = 0.046$), the CAN− group ($r = 0.37$, $P = 0.005$), and the entire diabetes group ($r = 0.24$, $P = 0.043$). Fasting C-peptide was also correlated with the 30:15 test in the CAN− group ($r = 0.34$, $P = 0.016$) and the entire diabetes group ($r = 0.26$, $P = 0.023$). However, no significant relationship of the Ewing test and residual $\beta$-cell function indexes was found in the control group.

**Logistic Regression Analysis of the Presence of CAN and Residual $\beta$-Cell Function Indexes**

Logistic regression was calculated to evaluate the independent association of the presence of CAN with fasting and 2-h postprandial plasma insulin and C-peptide levels, HOMA-B, HOMA-IR, and fasting plasma C-peptide strata.

Fasting plasma C-peptide and HOMA-B were independently and significantly associated with the presence of CAN ($P = 0.008$ and $P = 0.027$, respectively). No association of FINS ($P = 0.058$), 2-h postprandial plasma insulin ($P = 0.257$), 2-h postprandial plasma C-peptide ($P = 0.146$), and HOMA-IR ($P = 0.170$) with the presence of CAN was found (Fig. 2). After adjusting for age, fasting plasma C-peptide and HOMA-B were still significantly associated with the presence of CAN (OR, 0.041; 95% CI, 0.003–0.501; $P = 0.012$ and OR, 0.965; 95% CI, 0.934–0.996; $P = 0.028$, respectively).

There were 20 patients with CAN and 70 without CAN in the diabetes group (Fig. 3). Importantly, when the data were plotted against HbA1c, an independent association was found between low levels of fasting plasma C-peptide and CAN+. More specifically, a fasting plasma C-peptide level $\geq 0.67$ nmol/L, regardless of HbA1c, was associated with less CAN+. And the patients with C-peptide values $<0.67$ nmol/L were 6 times more likely to have CAN than those with C-peptide levels $\geq 0.67$ nmol/L (OR, 6.00; 95% CI, 1.815–19.830; $P = 0.003$) (Fig. 3).

**Discussion**

CAN, the possible cause of asymptomatic ischemia or myocardial infarction (MI), has been found to be associated with increased mortality in patients with diabetes, yet it remains one of the most overlooked complications of diabetes [16]. Previous studies have demonstrated that CAN is found in patients with newly-diagnosed diabetes, pre-diabetes, and even the first-degree relatives of type 2 diabetic patients with normal glucose tolerance [17, 18]. Although CAN progresses with the duration of diabetes [19], it can be reversed at the very early stage by interventions on risk factors [20], just like other nervous system diseases [21]. Hence, it is of great clinical importance to identify CAN and its characteristics in the early stage of the disease.

In this study, we targeted on newly-diagnosed and drug-naive type 2 diabetic patients for the early detection of CAN using the standard Ewing battery of tests. Our results showed that the index of the orthostatic hypotension test in the diabetes group was higher than that in the control group, while the index of the Valsalva ratio test was significantly lower in the diabetes group. These findings revealed an autonomic dysfunction in newly-diagnosed type 2 diabetic patients. Moreover, our results demonstrated that parasympathetic nerve activity was more
commonly and severely impaired than sympathetic nerve activity in this population. Eugenia Rota [22] found that the E/I test is abnormal in 28% of newly-diagnosed type 2 diabetic patients, and postural hypotension is present in 6% of that population, similar to our findings. However, sympathetic dysfunction (51.9%) has been found to be slightly more common than parasympathetic dysfunction (44.2%) in an Indian population with a relatively longer duration of diabetes [23]. These results might further suggest that parasympathetic nerve function is more vulnerable to hyperglycemia than sympathetic nerve function. Therefore, CAN, especially parasympathetic nerve dysfunction, can be detected once type 2 diabetes is diagnosed.

Hyperglycemia is a crucial pathophysiological factor in the development of CAN [2]. Previous studies have shown that autonomic nerve function improves significantly after blood glucose is well-controlled [1]. However, the fact that even achieving tight glycemic control may not prevent the progression of CAN [8] implies the importance of better understanding and exploring other related factors. In recent

### Table 5 Pearson’s correlation between Ewing tests and residual β-cell function indexes in diabetes groups.

|                          | Fasting plasma insulin | 2h postprandial plasma insulin |
|--------------------------|------------------------|--------------------------------|
|                          | CAN+  | CAN−  | Entire group | CAN+  | CAN−  | Entire group |
|                          | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) |
| Valsalva ratio           | 0.32  | 0.211 | 0.20  | 0.140 | 0.12  | 0.318 | 0.28  | 0.269 | 0.25  | 0.071 | 0.20  | 0.103 |
| E/I                     | 0.27  | 0.291 | 0.16  | 0.246 | 0.01  | 0.991 | 0.12  | 0.659 | 0.11  | 0.448 | 0.02  | 0.893 |
| 30:15 test              | 0.42  | 0.095 | 0.06  | 0.694 | 0.13  | 0.297 | 0.23  | 0.374 | 0.12  | 0.396 | 0.02  | 0.848 |
| Orthostatic hypotension test | 0.19  | 0.462 | −0.03 | 0.831 | −0.05 | 0.678 | −0.02 | 0.944 | −0.11 | 0.443 | −0.06 | 0.648 |

|                          | Fasting plasma C-peptide | 2h postprandial plasma C-peptide |
|--------------------------|--------------------------|----------------------------------|
|                          | CAN+  | CAN−  | Entire group | CAN+  | CAN−  | Entire group |
|                          | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) |
| Valsalva ratio           | 0.48  | 0.046* | 0.37  | 0.005* | 0.24  | 0.043* | 0.29  | 0.257 | 0.02  | 0.901 | 0.05  | 0.674 |
| E/I                     | 0.17  | 0.512 | 0.02  | 0.914 | 0.12  | 0.318 | 0.07  | 0.784 | 0.10  | 0.458 | 0.03  | 0.810 |
| 30:15 test              | 0.17  | 0.500 | 0.34  | 0.016* | 0.26  | 0.023* | 0.03  | 0.990 | 0.01  | 0.918 | 0.15  | 0.200 |
| Orthostatic hypotension test | −0.10 | 0.685 | −0.13 | 0.341 | −0.01 | 0.915 | −0.24 | 0.350 | −0.02 | 0.908 | −0.08 | 0.515 |

|                          | HOMA-IR | HOMA-B |
|--------------------------|---------|--------|
|                          | CAN+  | CAN−  | Entire group | CAN+  | CAN−  | Entire group |
|                          | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) | \( r \) | \( P \) |
| Valsalva ratio           | 0.32  | 0.215 | 0.20  | 0.148 | 0.13  | 0.259 | 0.19  | 0.457 | 0.16  | 0.255 | 0.17  | 0.154 |
| E/I                     | 0.15  | 0.558 | 0.13  | 0.347 | 0.04  | 0.754 | 0.34  | 0.183 | 0.16  | 0.249 | 0.12  | 0.313 |
| 30:15 test              | 0.35  | 0.173 | 0.13  | 0.368 | 0.13  | 0.265 | 0.38  | 0.136 | 0.08  | 0.558 | 0.06  | 0.649 |
| Orthostatic hypotension test | −0.19 | 0.459 | −0.08 | 0.591 | −0.08 | 0.511 | −0.06 | 0.829 | −0.06 | 0.665 | −0.07 | 0.574 |

CAN+, type 2 diabetic patients with cardiovascular autonomic neuropathy; CAN−, type 2 diabetic patients without cardiovascular autonomic neuropathy; E/I, deep-breathing test (expiration-to-inspiration ratio); 30:15 test, lying-to-standing test; \( *P < 0.05 \).
years, the role of β-cell function in diabetes-related complications has been demonstrated in different studies. Studies of type 1 diabetes suggest that residual endogenous insulin secretion reflected by C-peptide concentrations may have favorable effects on protection against the microvascular complications. In the Diabetes Control and Complications Trial, higher and sustained levels of stimulated C-peptide are associated with reduced incidence of retinopathy, nephropathy, and hypoglycemia [24]. In another study, urinary albumin excretion along with heart rate variability significantly improved in type 1 diabetic patients who received 6-month combination treatment of C-peptide and insulin [9], indicating that C-peptide and insulin improve renal and autonomic nerve function in type 1 diabetes. The potential mechanisms for these effects include the roles of C-peptide in the activation of Na/K channels, anti-inflammatory action, and improvement of nitric oxide bioavailability and endothelial function [25].

Type 2 diabetes has an underlying pathophysiology completely different from type 1 diabetes, especially the β-cell functional deterioration at the onset and development of the disease. And the findings on the relationship between β-cell function and diabetic complications in patients with type 2 diabetes are still controversial. Studies have shown that reduced β-cell function, reflected by lower fasting C-peptide and stimulated C-peptide levels, is associated with diabetic retinopathy, nephropathy, and peripheral neuropathy but not macrovascular complications in type 2 diabetic patients [26]. However, another study found an association between serum C-peptide and macrovascular rather than microvascular diabetic complications [27]. Nevertheless, little attention has been paid to the association between residual β-cell function and CAN in type 2 diabetes. In the present study, we found that diabetic patients with CAN were characterized by decreased residual β-cell function compared with diabetic patients without CAN and the control group, represented by lower fasting plasma insulin, plasma C-peptide, and HOMA-B. Moreover, further analysis revealed that the fasting plasma C-peptide and HOMA-B were independently and closely associated with CAN. More interestingly, our data showed that a fasting plasma C-peptide level <0.67 nmol/L was associated with the presence of CAN in this population, regardless of HbA1c levels. Taken together, our results support a close relationship of β-cell function with the presence of CAN in newly-diagnosed type 2 diabetic patients. We note that some other studies have contrary results. A previous study found that a higher serum C-peptide level is significantly associated with the presence of autonomic neuropathy [27]. We considered several reasons for this discrepancy, including the different study designs, ethnicity, degree of obesity, the longer duration of diabetes, and adoption of the orthostatic test but not the standard Ewing battery of tests to assess CAN in that study. With the longer disease duration and the impact of various hypoglycemic agents used by the patients, the residual β-cell function of the patients in that study differed to a great extent from the newly-diagnosed and drug-naïve patients in our study. Regarding the method used to assess CAN, the orthostatic test was used to identify sympathetic nerve dysfunction but not all autonomic function. Indeed, these differences among the studies again highlight the complexity of the relationship between β-cell function and CAN in type 2 diabetes.

One of the strengths of this study is that the participants were newly-diagnosed and drug-naïve patients, so that many confounding factors like disease duration and impact of hypoglycemic agents were avoided. By revealing the relationship between the residual β-cell function and CAN in this population, our results suggested that in the attempt to delay the natural course of CAN, preserving β-cell function should be one of the important strategies of
treating type 2 diabetes once it is diagnosed. Certain strategies, such as initiating insulin therapy as early as possible and avoiding drugs that over-stimulate β-cell function might be advocated to rescue β-cell function and eventually protect autonomic function. Another strength of our study is the adoption of the standard Ewing battery of tests to guarantee validation of the CAN diagnosis.

Some limitations of this study should be addressed in the interpretation of the results. The sample size was relatively small. And as the patients in this study were enrolled under hospital-based circumstances, they might not be the representative of the entire population of diabetic patients. And it might seem to be a limitation that other methods to detect CAN such as heart rate variability (HRV) or heart rate turbulence (HRT) [28, 29] were not used in our study. According to the Toronto Diabetic Neuropathy Expert Group, cardiovascular reflex tests (Ewing tests) are recommended as the gold standard in clinical autonomic testing because of the good sensitivity, specificity, and reproducibility, as well as being noninvasive, safe, well standardized, and easily performed [1]. Besides, HRV and HRT have no definite standard values for the diagnosis of CAN as the Ewing tests do [28]. That is why we decided to use Ewing tests. Therefore, we consider that our findings provide suggestive hints of an independent and close relationship of residual β-cell function with CAN in newly-diagnosed type 2 diabetic patients. The protection of β-cell function should not be neglected as an important component of the management of diabetes when therapeutic strategies are considered.

Conclusions

Cardiovascular autonomic nerves have already been damaged when type 2 diabetes mellitus is diagnosed. Parasympathetic nerves are more commonly and severely impaired than sympathetic at the early stage of the disease. Decreased β-cell function is associated with the presence of CAN in this population. Better residual β-cell function might be associated with decreased incidence of CAN in newly-diagnosed patients with type 2 diabetes.

Acknowledgements This work was supported by the Medical Scientific Research Foundation of Guangdong Province of China (A2018286) and the Key Projects of Clinical Disciplines of Hospitals Affiliated to Ministry of Health from Ministry of Health of China (A1781).

Conflict of interest All authors claim that there are no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33: 2285–2293.
2. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115: 387–397.
3. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010, 33: 1578–1584.
4. Pierson CR, Zhang W, Murakawa Y, Sima AA. Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol 2003, 62: 260–271.
5. Pierson CR, Zhang W, Sima AA. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropathol Exp Neurol 2003, 62: 765–779.
6. Li ZG, Zhang W, Sima AA. C-peptide prevents hippocampal apoptosis in type 1 diabetes. Int J Exp Diabetes Res 2002, 3: 241–245.
7. Najem D, Bamji-Mirza M, Yang Z, Zhang W. Abeta-induced insulin resistance and the effects of insulin on the cholesterol synthesis pathway and Abeta secretion in neural cells. Neurosci Bull 2016, 32: 227–238.
8. Kuo JZ, Guo X, Klein R, Klein BE, Weinreb RN, Genter P, et al. Association of fasting insulin and C peptide with diabetic retinopathy in Latinos with type 2 diabetes. BMJ Open Diabetes Res Care 2014, 2: e27.
9. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incident nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000, 17: 181–189.
10. Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999, 107: 40–45.
11. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995, 44: 796–801.
12. Boz M, Scheen AJ, Gerard PL, Castillo MJ, Lefebvre PJ. Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes. Diabetes Metab 1995, 21: 353–359.
13. Xu W, Zhu Y, Yang X, Deng H, Yan J, Lin S, et al. Glycemic variability is an important risk factor for cardiovascular autonomic neuropathy in newly diagnosed type 2 diabetic patients. Int J Cardiol 2016, 215: 263–268.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–419.
15. Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, Bax G, et al. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 2011, 21: 69–78.
16. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig 2013, 4: 4–18.
17. Pal GK, Adithan C, Anantharayanan PH, Pal P, Nanda N, Durgadevi T, et al. Effects of gender on sympathovagal imbalance, prehypertension status, and cardiovascular risks in first-degree relatives of type 2 diabetics. Am J Hypertens 2014, 27: 317–324.
18. Dimova R, Tankova T, Chakarova N, Groseva G, Dakovska L. Cardiovascular autonomic tone relation to metabolic parameters and hsCRP in normoglycemia and prediabetes. Diabetes Res Clin Pract. 2015; 109: 262–270.
19. Foss CH, Vestbo E, Froland A, Gjessing HJ, Mogensen CE, Damsgaard EM. Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia Study. Diabetes 2001, 50: 630–636.
20. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119: 2886–2893.
21. Li J, Wang Y. Blood biomarkers in minor stroke and transient ischemic attack. Neurosci Bull 2016, 32: 463–468.
22. Rota E, Quadri R, Fanti E, Poglio F, Paolasso I, Ciaramitaro P, et al. Clinical and electrophysiological correlations in type 2 diabetes mellitus at diagnosis. Diabetes Res Clin Pract 2007, 76: 152–154.
23. Jyotsna VP, Sahoo A, Sreenivas V, Deepak KK. Prevalence and pattern of cardiac autonomic dysfunction in newly detected type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 83: 83–88.
24. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26: 832–836.
25. Ekberg K, Johansson BL. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res 2008, 2008: 457912.
26. Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 2012, 49: 9–15.
27. Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 2005, 97: 1113–1118.
28. Bisssinger A, Ruxer J, Ahmed RB, Lubinski A. Heart rate turbulence in patients with poorly controlled diabetes mellitus type 2. Arch Med Sci 2014, 10: 1073–1077.
29. Faulkner MS, Quinn L, Fritschi C. Microalbuminuria and heart rate variability in adolescents with diabetes. J Pediatr Health Care 2010, 24: 34–41.